-
-
subtotal : ₹ 00.00
-
New Test Targets EBV Response in MS Patients
Trinity College Dublin unveils a groundbreaking blood test to gauge the immune response to Epstein-Barr virus (EBV) in multiple sclerosis (MS) patients. Recent studies increasingly link EBV to MS development, prompting a shift towards targeting EBV infection in MS treatment.
The test, developed by Trinity's research scientists, offers a vital outcome measure for future clinical trials in MS patients. By measuring the immune response to anti-viral treatments, it paves the way for more targeted therapies.
MS patients often cite fatigue as the most debilitating symptom, aligning with EBV's impact on the immune system. Trinity's study demonstrates elevated EBV immune responses in untreated MS patients compared to healthy individuals or those with epilepsy.
Excitingly, Trinity's test utilizes existing diagnostic equipment and can yield results within 24 hours. Its scalability and simplicity hold promise for widespread adoption and integration into MS treatment protocols.
Looking ahead, Trinity aims to validate the test's efficacy in longitudinal studies and collaborate with industry partners to integrate it into clinical trials. With EBV as a potential target, the future of MS treatment may be within reach.
